ArticleCell2021
Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Pooled it
- SARS-CoV-2 defective viral genomes from distinct genomic regions drive divergent interferon responses.PLoS pathogens · 2026Article
- The architecture of computational antiviralism: a multi-scale framework from molecular targeting to viral ecosystem engineering.Molecular diversity · 2026Review
- Coevolutionary dynamics of viruses and their defective interfering particles.PLoS computational biology · 2026Article
- Coronavirus genome packaging and nucleocapsid assembly.Journal of virology · 2026Review
- Classification, functions, evolution, and applications of defective viral genomes.Frontiers in microbiology · 2026Review
- Infection-sensing minigenome as a novel therapeutic approach against Ebola virus.Molecular therapy. Nucleic acids · 2025Article
- Characterization of the binding features between SARS-CoV-2 5'-proximal transcripts of genomic RNA and nucleocapsid proteins.RNA biology · 2025Review
- Live attenuated influenza vaccine with low proportions of defective interfering particles elicits robust immunogenicity and cross-protection.Nature communications · 2025Article
- Coevolutionary dynamics of viruses and their defective interfering particles.bioRxiv : the preprint server for biology · 2025Article
- Matryoshka Dolls of Virus Evolution: The Internal Forces That Shape Viral Fate.Integrative and comparative biology · 2025Article
- Intracellular interactions shape antiviral resistance outcomes in poliovirus via eco-evolutionary feedback.bioRxiv : the preprint server for biology · 2025Article
- Article
- Definition of the components required for selective packaging of coronavirus genomic RNA.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population.Journal of virology · 2025Article
- Review
- Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy.Molecular therapy. Nucleic acids · 2025Article
- Navigating a Fine Balance: Point-Mutant Cheater Viruses Disrupt the Viral Replication Cycle.Molecular biology and evolution · 2025Article
- Methods for the Detection, Purification, and Production of Defective Viral Genomes During Respiratory Syncytial Virus Infection.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Antivirotics based on defective interfering particles: emerging concepts and challenges.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 3 institutions in 1 country.
Sonali ChaturvediGladstone|UCSF Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA 94158, USA. Electronic address: sonali.chaturvedi@gladstone.ucsf.edu.
Gustavo VasenGladstone|UCSF Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA 94158, USA.
Michael PabloGladstone|UCSF Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA 94158, USA.
Xinyue ChenGladstone|UCSF Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA 94158, USA.
Nathan BeutlerDepartment of Medicine, University of California, San Diego, San Diego, CA 92121, USA.
Arjun KumarGladstone|UCSF Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA 94158, USA.
Elizabeth TannerGladstone|UCSF Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA 94158, USA.
Sylvia IllouzVxBiosciences Inc., Berkeley, CA 94707, USA.
Donna RahgoshayVxBiosciences Inc., Berkeley, CA 94707, USA.
John BurnettBeckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Leo HolguinBeckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Pei-Yi ChenGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA 94158, USA.
Blaise NdjamenHistology and Light Microscopy Core, Gladstone Institutes, San Francisco, CA 94158, USA.
Melanie OttGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA 94158, USA.
Robert RodickVxBiosciences Inc., Berkeley, CA 94707, USA.
Thomas RogersDepartment of Medicine, University of California, San Diego, San Diego, CA 92121, USA.
Davey M SmithDepartment of Medicine, University of California, San Diego, San Diego, CA 92121, USA.
Leor S WeinbergerGladstone|UCSF Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: leor.weinberger@gladstone.ucsf.edu.
Gladstone Institutes · USUniversity of California San Diego · USCity of Hope · US
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MA Gene Drive Therapy for HIV: Single-Administration Intervention for High-RiskGroupsDP1DA051144 · NIDA · J. DAVID GLADSTONE INSTITUTES · PI WEINBERGER, LEOR S · 2020 to 2024
$5.7MAutonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic preventionR01AI169443 · NIAID · VXBIOSCIENCES, INC. · PI RODICK, ROBERT, WEINBERGER, LEOR S · 2021 to 2023
$4.8MBD FACSAria II Flow CytometerS10RR028962 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI CAVROIS, MARIELLE · 2011 to 2011
$544kNCRR NIH HHS S10 RR028962NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI169443NIDA NIH HHS DP1 DA051144
Abstract
Viral-deletion mutants that conditionally replicate and inhibit the wild-type virus (i.e., defective interfering particles, DIPs) have long been proposed as single-administration interventions with high genetic barriers to resistance. However, theories predict that robust, therapeutic DIPs (i.e., therapeutic interfering particles, TIPs) must conditionally spread between cells with R
Indexed as
COVID-19 Drug TreatmentAnimalsAntiviral AgentsCell LineChlorocebus aethiopsCOVID-19Culture Media, ConditionedDefective Interfering VirusesDrug Delivery SystemsEpithelial CellsHumansMaleMesocricetusNanoparticlesSARS-CoV-2Vero CellsAntiviral AgentsCulture Media, Conditionedcoronavirusdefective interfering particlesevolutionintranasallipid nanoparticleRNASARS-CoV-2therapeutic interfering particlesvariantsvirus-like particle
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.